KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Short-term Investments (2017 - 2025)

Guardant Health (GH) has disclosed Short-term Investments for 9 consecutive years, with $823.4 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 161.86% to $823.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $823.4 million through Dec 2025, up 161.86% year-over-year, with the annual reading at $823.4 million for FY2025, 161.86% up from the prior year.
  • Short-term Investments hit $823.4 million in Q4 2025 for Guardant Health, up from $314.4 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $1.1 billion in Q1 2021 to a low of $35.1 million in Q4 2023.
  • Historically, Short-term Investments has averaged $637.5 million across 5 years, with a median of $697.5 million in 2023.
  • Biggest five-year swings in Short-term Investments: plummeted 95.96% in 2023 and later surged 795.91% in 2024.
  • Year by year, Short-term Investments stood at $440.5 million in 2021, then skyrocketed by 97.39% to $869.6 million in 2022, then tumbled by 95.96% to $35.1 million in 2023, then soared by 795.91% to $314.4 million in 2024, then surged by 161.86% to $823.4 million in 2025.
  • Business Quant data shows Short-term Investments for GH at $823.4 million in Q4 2025, $314.4 million in Q4 2024, and $310.7 million in Q3 2024.